Enanta Pharmaceuticals (ENTA) said late Tuesday it has filed a notice of appeal with the US Court of Appeals for the Federal Circuit in its patent infringement lawsuit against Pfizer (PFE), seeking damages related to the manufacture, use, and sale of COVID-19 antiviral, Paxlovid.
The company said the appeal follows a ruling by the Federal Circuit affirming last December's judgment by a US District Court, which found Enanta's claims invalid.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.